Available Technologies
# of Displayed Technologies: 3 / 3
Applied Category Filter (Click To Remove): Hematology, Blood & Lymphatic
Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 —
CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need
More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
- College: College of Medicine (COM)
- Inventors: Ranganathan, Parvathi; Garzon, Ramiro
- Licensing Officer: He, Panqing
Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights …
- College: College of Medicine (COM)
- Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
- Licensing Officer: He, Panqing
miR-3151 and BAALC as a Target for Drug Therapy
TS-014895 — Identified gene target for treatment of human acute leukemia, brain tumors and melanoma
Treatment failure is one of the leading causes of death in patients with human acute leukemia, yet the cause of treatment failure is still largely unknown. Overexpression of the RNA gene miR-3151 and its host gene, Brain and Acute Leukemia, Cytplasmic (BAALC), is a sign of an ineffective treatment…
- College: College of Medicine (COM)
- Inventors: de la Chapelle, Albert; Eisfeld, Ann-Kathrin; Tanner, Stephan
- Licensing Officer: Schworer, Adam
